30 closest matches · ranked by relevance
Japanese Encephalitis · Hepatitis A
Primary: Number of Participants With Solicited Injection Site and Systemic Reactions After Injection With Either JE-CV or Hepatitis A Vaccine as First Injection — 15; 13; NA; NA…
Influenza Prophylaxis
Primary: Change in Geometric Mean Titre Ratio, A/H1N1 Strain — 3.13; 3.17 Ratio of Day 0 and Day 21-28 titres
Japanese Encephalitis
Primary: Primary: 1. Geometric Mean Titers (GMT) at Day 56 — 100.1; 84.7; 68.1 Geometric Mean Titer - Estimate
Influenza · Orthomyxoviruses · Myxovirus Infection
Primary: Summary of the Pre- and Post-Vaccination Geometric Mean Titers (GMTs) for Each of the Influenza Vaccine Antigens. — 25.9; 26.4; 26.6; 184.8 Titers
Influenza
Primary: Serum Haemagglutination-inhibition (HI) Antibody Titers, Against Each of the Vaccine Influenza Virus Strains. — 21.4; 22.2; 23.3; 18.4 Titer
Influenza
Primary: Hemagglutination Inhibition (HI) Geometric Mean Titers (GMTs) of TIV Group and TIVf Group for All Three Strains, in Healthy Adults Aged ≥50 Years — 315; 581; 697; 1048…
Japanese Encephalitis
Primary: SCR (Seroconversion Rate)of IC51 Compared to JE-VAX at Day 56 — 96.4; 93.6 percentage of participants
Japanese Encephalitis
Primary: Percentage of Subjects With Seroconversion Rate (SCR) ≥ 1:10 Anti-JEV Neutralizing Antibody Titer (PRNT) — 81.8 percentage of subjects
HPV Seroconversion
Primary: Number of Participants With Geometric Mean Antibody Concentrations by HPV Type — 15; 12; 8; 4 Participants
Influenza
Primary: Immunogenicity - Geometric Mean Titer Fold Increase From Baseline — 3.5; 4.0; 4.5; 3.4 GMT fold increase
Rabies Virus
Primary: Rabies Virus Neutralizing Antibody (RVNA) Geometric Mean Titers (GMTs) Against Rabies Virus at Day 0 — 0.101; 0.100; 0.102; 0.101 international units per milliliter
Rabies
Primary: Protective Humoral Immune Response at 1 Month Post First Vaccination. — 12; 12; 12; 11 Participants
Influenza
Primary: Geometric Mean Titer — 3.36; 2.61; 2.46; 2.41 GMT fold increase from baseline
HIV Infections
Primary: Number of Participants With Moderate or Greater Reactogenicity (i.e., Solicited Adverse Events) — 2; 4 Participants
Poliomyelitis
Primary: Number of Participants Experiencing Any Systemic Reactogenicity, by Maximum Severity — 187; 179; 175; 149 Participants
Hepatitis B Vaccine
Primary: Number and Percentage of Participants With Anti-HBs Seroconversion at Month 7 — 75; 69 Participants
Pandemic · Avian Influenza
Primary: Number Subjects Who Responded to Two or Three Vaccinations of the MF59-H5N1 Influenza Vaccine — 0; 1; 0; 2 Subjects
Influenza
Primary: Adverse Events by Severity — 20; 8; 25; 8 Participants
Hepatitis B · Polio · Diphtheria
Primary: Percentage of Participants With Anti HBs Seroprotection After the 3 Dose Primary Vaccination Series With Either DTaP-IPV-Hep B-PRP~T or PENTAXIM™ + ENGERIX B® Vaccines…
Systemic Lupus Erythematosus
Primary: Anti-HPV 6 Seroconversion — 93.8 percentage of participants
Orthomyxoviridae Infection · Influenza · Myxovirus Infection
Primary: Geometric Mean Titers (GMTs) of Hemagglutination Inhibition Antibody Titers Pre- and Post-vaccination With Fluzone® High Dose or Standard Fluzone® Vaccines. — 28.25…
Human Influenza
Primary: Increase in Geometric Mean Titre Ratio, A/H1N1 Strain — 4.337; 4.702 Ratio of Day 0 and Day 21-28 titres
Encephalitis
Primary: Change From Baseline in Geometric Mean Titers Against the Japanese Encephalitis Chimeric Virus at 28 Days Post Vaccination — 9144 titers
Influenza
Primary: Microneutralization (MN) Assay Response to Cell-grown Influenza A/H3N2 - Seroconversion Rate (SCR) — 112; 48; 29 Participants
Pandemic H5N1 Influenza
Primary: The Percentages Of Subjects Achieving Hemagglutination Inhibition (HI) Titers ≥40 Against A/H5N1 Strain. — 12; 10; 81; 63 Percentages of subjects
Influenza
Primary: Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 3 Strains of Influenza Disease. — 13.0; 12.3; 12.9; 14.9 titers
Pandemic H5N1 Influenza
Primary: Percentages Of Subjects Achieving Hemagglutinin Inhibition (HI) Titers ≥40 Against A/H5N1 Strain. — 4; 4; 85; 63 Percentages of subjects
Dengue Fever
Primary: Geometric Mean Titers (GMT) of Neutralizing Antibodies for Each of the Four Dengue Serotypes at Day 15 — 58.9; 15325.2; 5510.0; 11.2 titer
Encephalitis
Primary: Rate of Subjects With Serious Adverse Events (SAEs) and Medically Attended AEs up to Day 56 After the First Vaccination — 33.3; 20.7; 3.4 percentage of participants
Hepatitis B Vaccines
Primary: Seroprotection Rate (SPR) Defined as Percentage of Adults ≥ 18 Years Old Achieving Anti-HBs Levels of ≥10 mIU/mL in Serum at Study Day 196 — 76.49; 91.36 percentage of…